Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Testen der Zugabe von BMS-986016 (Relatlimab) zur üblichen Immuntherapie nach der Erstbehandlung von rezidivierendem oder metastasiertem Nasopharynxkrebs

5. November 2026 aktualisiert von: National Cancer Institute (NCI)

Eine randomisierte Phase-II-Studie zu Nivolumab im Vergleich zu Nivolumab und BMS-986016 (Relatlimab) als Erhaltungstherapie nach Erstlinienbehandlung mit Platin-Gemcitabin-Nivolumab für Patienten mit Epstein-Barr-Virus-assoziiertem rezidivierendem/metastasiertem Nasopharynxkarzinom (REMAIN)

This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Relatlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. The usual approach of treatment is initial treatment with chemotherapy such as the combination of cisplatin (or carboplatin) and gemcitabine, along with immunotherapy such as nivolumab. After the initial treatment is finished, patients may continue to receive additional immunotherapy. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. Giving BMS-986016 in addition to the usual immunotherapy after initial treatment may extend the time without the tumor cells growing or spreading longer than the usual approach in patients with recurrent or metastatic nasopharyngeal cancer.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

PRIMARY OBJECTIVE:

I. To determine if adding BMS-986016 (relatlimab) to nivolumab maintenance therapy shows a signal of improved progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 in patients who do not progress following treatment with platinum-gemcitabine-nivolumab combination in the first-line treatment of recurrent and/or metastatic nasopharyngeal carcinoma (R/M NPC).

SECONDARY OBJECTIVES:

I. To determine if adding BMS-986016 (relatlimab) to nivolumab maintenance improves overall survival (OS) compared to nivolumab maintenance alone.

II. To compare patterns of failure (local-regional relapse and distant metastasis) between treatment arms.

III. To determine if adding BMS-986016 (relatlimab) to nivolumab maintenance improves objective response, duration of response, and disease control rate compared to nivolumab maintenance alone.

IV. To evaluate the tolerability of nivolumab-BMS-986016 (relatlimab) maintenance and assess and compare toxicity between arms based on the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0) criteria.

V. To evaluate baseline plasma Epstein-Barr virus (EBV) DNA (< 2000 copies/mL versus [vs.] >= 2000 copies/mL) as a prognostic biomarker.

VI. To validate post-induction plasma EBV DNA (detectable [>= 1 copies/mL] vs. undetectable [0 copies/mL]) as a prognostic biomarker.

EXPLORATORY OBJECTIVES:

I. To collect blood and tissue specimens for future translational science studies.

II. To assess post-induction plasma EBV DNA (detectable [>= 1 copies/mL] vs. undetectable [0 copies/mL]) as a predictive biomarker.

OUTLINE:

INDUCTION THERAPY: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1 of each cycle, cisplatin IV or carboplatin IV over 30-60 minutes on day 1 of each cycle and gemcitabine IV over 30 minutes on days 1 and 8 of each cycle. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) or magnetic resonance imaging (MRI) and blood sample collection during screening and on study.

MAINTENANCE THERAPY: Patients who do not progress radiologically are randomized to 1 of 2 arms.

ARM I: Patients receive nivolumab IV over 30 minutes. Cycles repeat every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI on study. Patients also undergo positron emission tomography (PET)/CT or bone scan as clinically indicated.

ARM II: Patients receive nivolumab IV over 30 minutes and relatlimab IV over 30-90 minutes. Cycles repeat every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI on study. Patients also undergo PET/CT or bone scan as clinically indicated.

After completion of study treatment, patients are followed up every 4 months for 2 years, every 6 months in years 3-5, and then annually.

Studientyp

Interventionell

Einschreibung (Geschätzt)

156

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Australien
    • Victoria
      • Melbourne, Victoria, Australien, 3000
        • Rekrutierung
        • Peter MacCallum Cancer Centre
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 61 3 9656 1521
        • Hauptermittler:
          • Danny Rischin
  • Hongkong
      • Shatin, Hongkong
        • Rekrutierung
        • Chinese University of Hong Kong-Prince of Wales Hospital
        • Kontakt:
        • Hauptermittler:
          • Brigette B. Ma
  • Kanada
    • Ontario
      • Toronto, Ontario, Kanada, M5G 2M9
        • Rekrutierung
        • University Health Network-Princess Margaret Hospital
        • Kontakt:
        • Hauptermittler:
          • Enrique Sanz Garcia
  • Singapur
      • Singapore, Singapur, 119074
        • Rekrutierung
        • National University Hospital Singapore
        • Kontakt:
        • Hauptermittler:
          • Boon C. Goh
      • Singapore, Singapur, 168583
        • Rekrutierung
        • National Cancer Centre Singapore
        • Kontakt:
        • Hauptermittler:
          • Wan Teck D. Lim
  • Vereinigte Staaten
    • California
      • Dublin, California, Vereinigte Staaten, 94568
        • Rekrutierung
        • Kaiser Permanente Dublin
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
        • Hauptermittler:
          • Jed A. Katzel
      • Fremont, California, Vereinigte Staaten, 94538
        • Rekrutierung
        • Kaiser Permanente-Fremont
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-Mail: Kpoct@kp.org
        • Hauptermittler:
          • Jed A. Katzel
      • Fresno, California, Vereinigte Staaten, 93720
        • Rekrutierung
        • Kaiser Permanente-Fresno
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-Mail: Kpoct@kp.org
        • Hauptermittler:
          • Jed A. Katzel
      • Fresno, California, Vereinigte Staaten, 93720
        • Rekrutierung
        • Kaiser Permanente Fresno Orchard Plaza
        • Hauptermittler:
          • Jed A. Katzel
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 833-574-2273
      • Los Angeles, California, Vereinigte Staaten, 90033
        • Rekrutierung
        • USC / Norris Comprehensive Cancer Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 323-865-0451
        • Hauptermittler:
          • Jacob S. Thomas
      • Los Angeles, California, Vereinigte Staaten, 90020
        • Rekrutierung
        • Keck Medicine of USC Koreatown
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 213-388-0908
        • Hauptermittler:
          • Jacob S. Thomas
      • Los Angeles, California, Vereinigte Staaten, 90033
        • Rekrutierung
        • Los Angeles General Medical Center
        • Hauptermittler:
          • Jacob S. Thomas
        • Kontakt:
      • Modesto, California, Vereinigte Staaten, 95356
        • Rekrutierung
        • Kaiser Permanente-Modesto
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-Mail: Kpoct@kp.org
        • Hauptermittler:
          • Jed A. Katzel
      • Modesto, California, Vereinigte Staaten, 95356
        • Rekrutierung
        • Kaiser Permanente- Modesto MOB II
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
        • Hauptermittler:
          • Jed A. Katzel
      • Newport Beach, California, Vereinigte Staaten, 92663
        • Rekrutierung
        • USC Norris Oncology/Hematology-Newport Beach
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 323-865-0451
        • Hauptermittler:
          • Jacob S. Thomas
      • Oakland, California, Vereinigte Staaten, 94611
        • Rekrutierung
        • Kaiser Permanente-Oakland
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-Mail: Kpoct@kp.org
        • Hauptermittler:
          • Jed A. Katzel
      • Palo Alto, California, Vereinigte Staaten, 94304
        • Rekrutierung
        • Stanford Cancer Institute Palo Alto
        • Hauptermittler:
          • Alexander D. Colevas
        • Kontakt:
      • Roseville, California, Vereinigte Staaten, 95661
        • Rekrutierung
        • Kaiser Permanente-Roseville
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-Mail: Kpoct@kp.org
        • Hauptermittler:
          • Jed A. Katzel
      • Sacramento, California, Vereinigte Staaten, 95817
        • Rekrutierung
        • University of California Davis Comprehensive Cancer Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 916-734-3089
        • Hauptermittler:
          • Siao-Yi Wang
      • Sacramento, California, Vereinigte Staaten, 95814
        • Rekrutierung
        • Kaiser Permanente Downtown Commons
        • Hauptermittler:
          • Jed A. Katzel
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-Mail: kpoct@kp.org
      • Sacramento, California, Vereinigte Staaten, 95823
        • Rekrutierung
        • Kaiser Permanente-South Sacramento
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-Mail: Kpoct@kp.org
        • Hauptermittler:
          • Jed A. Katzel
      • San Francisco, California, Vereinigte Staaten, 94115
        • Rekrutierung
        • Kaiser Permanente-San Francisco
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-Mail: Kpoct@kp.org
        • Hauptermittler:
          • Jed A. Katzel
      • San Jose, California, Vereinigte Staaten, 95119
        • Rekrutierung
        • Kaiser Permanente-Santa Teresa-San Jose
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-Mail: Kpoct@kp.org
        • Hauptermittler:
          • Jed A. Katzel
      • San Leandro, California, Vereinigte Staaten, 94577
        • Rekrutierung
        • Kaiser Permanente San Leandro
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-Mail: Kpoct@kp.org
        • Hauptermittler:
          • Jed A. Katzel
      • San Rafael, California, Vereinigte Staaten, 94903
        • Rekrutierung
        • Kaiser San Rafael-Gallinas
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-Mail: Kpoct@kp.org
        • Hauptermittler:
          • Jed A. Katzel
      • Santa Clara, California, Vereinigte Staaten, 95051
        • Rekrutierung
        • Kaiser Permanente Medical Center - Santa Clara
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-Mail: Kpoct@kp.org
        • Hauptermittler:
          • Jed A. Katzel
      • Santa Rosa, California, Vereinigte Staaten, 95403
        • Rekrutierung
        • Kaiser Permanente-Santa Rosa
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-Mail: Kpoct@kp.org
        • Hauptermittler:
          • Jed A. Katzel
      • South San Francisco, California, Vereinigte Staaten, 94080
        • Rekrutierung
        • Kaiser Permanente-South San Francisco
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-Mail: Kpoct@kp.org
        • Hauptermittler:
          • Jed A. Katzel
      • Vallejo, California, Vereinigte Staaten, 94589
        • Rekrutierung
        • Kaiser Permanente-Vallejo
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-Mail: Kpoct@kp.org
        • Hauptermittler:
          • Jed A. Katzel
      • Walnut Creek, California, Vereinigte Staaten, 94596
        • Rekrutierung
        • Kaiser Permanente-Walnut Creek
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 877-642-4691
          • E-Mail: Kpoct@kp.org
        • Hauptermittler:
          • Jed A. Katzel
    • Georgia
      • Atlanta, Georgia, Vereinigte Staaten, 30308
        • Rekrutierung
        • Emory University Hospital Midtown
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 888-946-7447
        • Hauptermittler:
          • Conor E. Steuer
    • Hawaii
      • Honolulu, Hawaii, Vereinigte Staaten, 96819
        • Rekrutierung
        • Kaiser Permanente Moanalua Medical Center
        • Kontakt:
        • Hauptermittler:
          • Jed A. Katzel
    • Idaho
      • Boise, Idaho, Vereinigte Staaten, 83706
        • Suspendiert
        • Saint Alphonsus Cancer Care Center-Boise
      • Caldwell, Idaho, Vereinigte Staaten, 83605
        • Suspendiert
        • Saint Alphonsus Cancer Care Center-Caldwell
      • Coeur d'Alene, Idaho, Vereinigte Staaten, 83814
        • Rekrutierung
        • Kootenai Health - Coeur d'Alene
        • Hauptermittler:
          • John M. Schallenkamp
        • Kontakt:
      • Nampa, Idaho, Vereinigte Staaten, 83687
        • Suspendiert
        • Saint Alphonsus Cancer Care Center-Nampa
      • Post Falls, Idaho, Vereinigte Staaten, 83854
        • Rekrutierung
        • Kootenai Clinic Cancer Services - Post Falls
        • Hauptermittler:
          • John M. Schallenkamp
        • Kontakt:
      • Sandpoint, Idaho, Vereinigte Staaten, 83864
        • Rekrutierung
        • Kootenai Clinic Cancer Services - Sandpoint
        • Hauptermittler:
          • John M. Schallenkamp
        • Kontakt:
    • Illinois
      • Chicago, Illinois, Vereinigte Staaten, 60612
        • Aktiv, nicht rekrutierend
        • University of Illinois
      • Chicago, Illinois, Vereinigte Staaten, 60611
        • Rekrutierung
        • Northwestern University
        • Kontakt:
        • Hauptermittler:
          • Jochen H. Lorch
      • Danville, Illinois, Vereinigte Staaten, 61832
        • Rekrutierung
        • Carle at The Riverfront
        • Hauptermittler:
          • Prem Sobti
        • Kontakt:
      • DeKalb, Illinois, Vereinigte Staaten, 60115
        • Rekrutierung
        • Northwestern Medicine Cancer Center Kishwaukee
        • Kontakt:
        • Hauptermittler:
          • Jochen H. Lorch
      • Effingham, Illinois, Vereinigte Staaten, 62401
        • Rekrutierung
        • Carle Physician Group-Effingham
        • Kontakt:
        • Hauptermittler:
          • Prem Sobti
      • Geneva, Illinois, Vereinigte Staaten, 60134
        • Rekrutierung
        • Northwestern Medicine Cancer Center Delnor
        • Kontakt:
        • Hauptermittler:
          • Jochen H. Lorch
      • Glenview, Illinois, Vereinigte Staaten, 60026
        • Rekrutierung
        • Northwestern Medicine Glenview Outpatient Center
        • Hauptermittler:
          • Jochen H. Lorch
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 312-695-1102
      • Grayslake, Illinois, Vereinigte Staaten, 60030
        • Rekrutierung
        • Northwestern Medicine Grayslake Outpatient Center
        • Hauptermittler:
          • Jochen H. Lorch
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 312-695-1102
      • Lake Forest, Illinois, Vereinigte Staaten, 60045
        • Rekrutierung
        • Northwestern Medicine Lake Forest Hospital
        • Kontakt:
        • Hauptermittler:
          • Jochen H. Lorch
      • Mattoon, Illinois, Vereinigte Staaten, 61938
        • Rekrutierung
        • Carle Physician Group-Mattoon/Charleston
        • Kontakt:
        • Hauptermittler:
          • Prem Sobti
      • Orland Park, Illinois, Vereinigte Staaten, 60462
      • Urbana, Illinois, Vereinigte Staaten, 61801
        • Rekrutierung
        • Carle Cancer Center
        • Kontakt:
        • Hauptermittler:
          • Prem Sobti
      • Warrenville, Illinois, Vereinigte Staaten, 60555
        • Rekrutierung
        • Northwestern Medicine Cancer Center Warrenville
        • Kontakt:
        • Hauptermittler:
          • Jochen H. Lorch
    • Iowa
      • Ankeny, Iowa, Vereinigte Staaten, 50023
        • Rekrutierung
        • UI Health Care Mission Cancer and Blood - Ankeny Clinic
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 515-241-3305
        • Hauptermittler:
          • Seema Harichand-Herdt
      • Carroll, Iowa, Vereinigte Staaten, 51401
        • Rekrutierung
        • Saint Anthony Regional Hospital
        • Kontakt:
        • Hauptermittler:
          • Seema Harichand-Herdt
      • Clive, Iowa, Vereinigte Staaten, 50325
        • Rekrutierung
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 515-241-3305
        • Hauptermittler:
          • Seema Harichand-Herdt
      • Council Bluffs, Iowa, Vereinigte Staaten, 51503
        • Suspendiert
        • Heartland Oncology and Hematology LLP
      • Council Bluffs, Iowa, Vereinigte Staaten, 51503
        • Suspendiert
        • Methodist Jennie Edmundson Hospital
      • Council Bluffs, Iowa, Vereinigte Staaten, 51503
        • Suspendiert
        • Nebraska Cancer Specialists/Oncology Hematology West PC - MEJ
      • Des Moines, Iowa, Vereinigte Staaten, 50314
        • Rekrutierung
        • Broadlawns Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 515-282-2200
        • Hauptermittler:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, Vereinigte Staaten, 50314
        • Rekrutierung
        • Mercy Medical Center - Des Moines
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 515-241-3305
        • Hauptermittler:
          • Richard L. Deming
      • Des Moines, Iowa, Vereinigte Staaten, 50309
        • Rekrutierung
        • Iowa Methodist Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 515-241-6727
        • Hauptermittler:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, Vereinigte Staaten, 50309
        • Rekrutierung
        • UI Health Care Mission Cancer and Blood - Des Moines Clinic
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 515-241-3305
        • Hauptermittler:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, Vereinigte Staaten, 50314
        • Rekrutierung
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 515-241-3305
        • Hauptermittler:
          • Seema Harichand-Herdt
      • Fort Dodge, Iowa, Vereinigte Staaten, 50501
        • Rekrutierung
        • UI Healthcare Mission Cancer and Blood - Fort Dodge
        • Hauptermittler:
          • Seema Harichand-Herdt
        • Kontakt:
      • Waukee, Iowa, Vereinigte Staaten, 50263
        • Rekrutierung
        • UI Health Care Mission Cancer and Blood - Waukee Clinic
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 515-241-3305
        • Hauptermittler:
          • Seema Harichand-Herdt
    • Missouri
      • St Louis, Missouri, Vereinigte Staaten, 63128
        • Rekrutierung
        • Mercy Hospital South
        • Hauptermittler:
          • Jay W. Carlson
        • Kontakt:
      • St Louis, Missouri, Vereinigte Staaten, 63141
        • Rekrutierung
        • Mercy Hospital Saint Louis
        • Hauptermittler:
          • Jay W. Carlson
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 314-251-7066
    • Montana
      • Anaconda, Montana, Vereinigte Staaten, 59711
        • Rekrutierung
        • Community Hospital of Anaconda
        • Hauptermittler:
          • John M. Schallenkamp
        • Kontakt:
      • Billings, Montana, Vereinigte Staaten, 59101
        • Rekrutierung
        • Billings Clinic Cancer Center
        • Hauptermittler:
          • John M. Schallenkamp
        • Kontakt:
      • Bozeman, Montana, Vereinigte Staaten, 59715
        • Rekrutierung
        • Bozeman Health Deaconess Hospital
        • Hauptermittler:
          • John M. Schallenkamp
        • Kontakt:
      • Great Falls, Montana, Vereinigte Staaten, 59405
        • Rekrutierung
        • Benefis Sletten Cancer Institute
        • Hauptermittler:
          • John M. Schallenkamp
        • Kontakt:
      • Kalispell, Montana, Vereinigte Staaten, 59901
        • Rekrutierung
        • Logan Health Medical Center
        • Hauptermittler:
          • John M. Schallenkamp
        • Kontakt:
      • Missoula, Montana, Vereinigte Staaten, 59804
        • Rekrutierung
        • Community Medical Center
        • Hauptermittler:
          • John M. Schallenkamp
        • Kontakt:
    • Nebraska
      • Omaha, Nebraska, Vereinigte Staaten, 68114
        • Rekrutierung
        • Nebraska Cancer Specialists/Oncology Hematology West PC - MECC
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 402-334-4773
        • Hauptermittler:
          • Yungpo B. Su
      • Omaha, Nebraska, Vereinigte Staaten, 68114
        • Rekrutierung
        • Nebraska Methodist Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 402-354-5144
        • Hauptermittler:
          • Yungpo B. Su
      • Omaha, Nebraska, Vereinigte Staaten, 68114
        • Suspendiert
        • Oncology Associates PC
    • New Jersey
      • Basking Ridge, New Jersey, Vereinigte Staaten, 07920
        • Rekrutierung
        • Memorial Sloan Kettering Basking Ridge
        • Hauptermittler:
          • Alan L. Ho
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 212-639-7592
      • Middletown, New Jersey, Vereinigte Staaten, 07748
        • Rekrutierung
        • Memorial Sloan Kettering Monmouth
        • Hauptermittler:
          • Alan L. Ho
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 212-639-7592
      • Montvale, New Jersey, Vereinigte Staaten, 07645
        • Rekrutierung
        • Memorial Sloan Kettering Bergen
        • Hauptermittler:
          • Alan L. Ho
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 212-639-7592
    • New York
      • Commack, New York, Vereinigte Staaten, 11725
        • Rekrutierung
        • Memorial Sloan Kettering Commack
        • Hauptermittler:
          • Alan L. Ho
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 212-639-7592
      • Harrison, New York, Vereinigte Staaten, 10604
        • Rekrutierung
        • Memorial Sloan Kettering Westchester
        • Hauptermittler:
          • Alan L. Ho
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 212-639-7592
      • New York, New York, Vereinigte Staaten, 10065
        • Rekrutierung
        • Memorial Sloan Kettering Cancer Center
        • Hauptermittler:
          • Alan L. Ho
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 212-639-7592
      • Uniondale, New York, Vereinigte Staaten, 11553
        • Rekrutierung
        • Memorial Sloan Kettering Nassau
        • Hauptermittler:
          • Alan L. Ho
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 212-639-7592
    • Ohio
      • Cincinnati, Ohio, Vereinigte Staaten, 45219
        • Aktiv, nicht rekrutierend
        • University of Cincinnati Cancer Center-UC Medical Center
      • West Chester, Ohio, Vereinigte Staaten, 45069
        • Aktiv, nicht rekrutierend
        • University of Cincinnati Cancer Center-West Chester
    • Oklahoma
      • Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
        • Rekrutierung
        • University of Oklahoma Health Sciences Center
        • Kontakt:
        • Hauptermittler:
          • Minh Phan
      • Tulsa, Oklahoma, Vereinigte Staaten, 74146
        • Suspendiert
        • Oklahoma Cancer Specialists and Research Institute-Tulsa
    • Oregon
      • Ontario, Oregon, Vereinigte Staaten, 97914
        • Suspendiert
        • Saint Alphonsus Cancer Care Center-Ontario
      • Portland, Oregon, Vereinigte Staaten, 97213
        • Rekrutierung
        • Providence Portland Medical Center
        • Hauptermittler:
          • Dan S. Zuckerman
        • Kontakt:
      • Portland, Oregon, Vereinigte Staaten, 97225
        • Rekrutierung
        • Providence Saint Vincent Medical Center
        • Hauptermittler:
          • Dan S. Zuckerman
        • Kontakt:
    • South Carolina
      • Charleston, South Carolina, Vereinigte Staaten, 29425
        • Rekrutierung
        • Medical University of South Carolina
        • Kontakt:
        • Hauptermittler:
          • John M. Kaczmar
    • Washington
      • Seattle, Washington, Vereinigte Staaten, 98122
        • Rekrutierung
        • Swedish Medical Center-First Hill
        • Hauptermittler:
          • Dan S. Zuckerman
        • Kontakt:
    • Wisconsin
      • Mukwonago, Wisconsin, Vereinigte Staaten, 53149
        • Rekrutierung
        • ProHealth D N Greenwald Center
        • Kontakt:
        • Hauptermittler:
          • Timothy R. Wassenaar
      • Oconomowoc, Wisconsin, Vereinigte Staaten, 53066
        • Rekrutierung
        • ProHealth Oconomowoc Memorial Hospital
        • Hauptermittler:
          • Timothy R. Wassenaar
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 262-928-7878
      • Waukesha, Wisconsin, Vereinigte Staaten, 53188
        • Rekrutierung
        • ProHealth Waukesha Memorial Hospital
        • Hauptermittler:
          • Timothy R. Wassenaar
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 262-928-7632
      • Waukesha, Wisconsin, Vereinigte Staaten, 53188
        • Rekrutierung
        • UW Cancer Center at ProHealth Care
        • Hauptermittler:
          • Timothy R. Wassenaar
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • PRIOR TO STEP 1 REGISTRATION:

  • Pathologically (histologically or cytologically) proven diagnosis of nasopharyngeal carcinoma (NPC) that has recurred locoregionally and/or is present at distant sites. Patients who present with metastatic disease (de novo) at diagnosis are also eligible. For locoregional recurrence, the disease must not be amenable to potentially curative surgery or re-irradiation. Eligible patient must have the following characteristics:

    • Tumor showing (histological/cytological) Epstein-Barr encoded ribonucleic acid (EBER)-positivity (e.g., In situ hybridization, immunohistochemistry) or
    • A known history of detectable plasma EBV DNA (via a polymerase chain reaction [PCR]-based assay) at any time point since the initial diagnosis of NPC.

  • Measurable disease as defined by RECIST 1.1 criteria. Lesion(s) that have been irradiated previously can be counted as measurable as long as radiological progression after the prior radiation therapy has been demonstrated.

    • Contrast enhanced CT scan of the chest. The contrast enhanced CT component of a whole-body PET-CT is also acceptable. The plain (non-contrast) CT component of a PET-CT is not acceptable.
    • CT the abdomen and pelvis, if clinically indicated (diagnostic quality with contrast, unless contraindicated).
    • Patients with known locoregional disease must have contrast enhanced MRI or CT of the nasopharynx and neck as this disease site(s) may be assessed as target lesions. For patients without known locoregional disease, imaging of the nasopharynx and neck is optional.
    • Symptomatic and active brain metastases and/or leptomeningeal metastasis on CT and/or MRI imaging: Patients who have prior therapies for brain and leptomeningeal metastasis or cord/cauda compression who are clinically stable for >= 2 months prior to registration and have discontinued systemic steroids therapy (> 10 mg/day prednisone or equivalent) > 4 weeks prior to registration are eligible.
    • Patients with base of skull involvement by NPC are allowed unless their disease is directly invading the brain parenchyma, associated with clinical symptoms and/or significant vasogenic edema on radiological imaging.

  • Age >= 18 years.

  • Eastern Cooperative Oncology Group (ECOG) (Zubrod) performance status of 0-2.

  • Negative urine or serum pregnancy test (in persons of childbearing potential) within 14 days prior to registration. Childbearing potential is defined as any person who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal.

  • Absolute neutrophil count (ANC) >= 1500 cells/mm^3.

  • Platelets >= 100,000 cells/mm^3.

  • Hemoglobin (Hgb) >= 8.0 g/dL (Transfusion is accepted. Erythropoietin dependency not accepted.).

  • Total bilirubin =< 1.5 × institutional upper limit of normal (ULN) or direct bilirubin =< ULN for patients with total bilirubin levels > 1.5 × ULN. Patients with known Gilbert's disease who have serum bilirubin level =< 3 × ULN may be enrolled.

  • Alanine transaminase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 × ULN (=< 5 × ULN for patients with liver metastases).

  • Serum creatinine =< 1.5 × ULN or calculated creatinine clearance (CrCl) based on Cockcroft-Gault equation >= 30 mL/min for patients with serum creatinine levels > 1.5 × ULN. Cisplatin or carboplatin may be used at the discretion of the investigator - except for patients with CrCl between 30-50 mL/min, for whom carboplatin should be used instead of cisplatin. CrCl must be > 50 mL/min for cisplatin to be used.

  • Albumin-adjusted calcium level based on corrected calcium equation =< 1.5 × ULN (patients are allowed to have treatment for hypercalcemia prior to starting treatment).

  • No prior systemic treatment of palliative intent for recurrent/metastatic (R/M) NPC including cytotoxic chemotherapy. Prior treatment for non-recurrent and non-metastatic NPC is allowed. Systemic therapy given prior to curative intent re-irradiation or surgery is allowed for potentially curable locoregional recurrence.

  • No prior treatment with a PD-1 inhibitor (except if given as adjuvant or neoadjuvant therapy for NPC), PD-L1 inhibitor, anti-PD-L2 inhibitor, LAG-3 inhibitor, CTLA-4 inhibitor (except if given as adjuvant or neoadjuvant therapy for non-recurrent and non-metastatic NPC), or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.

  • The interval between the last dose of curative-intent treatment for non-recurrent, non-metastatic NPC, including definitive radiotherapy (RT) and/or induction, concurrent, or adjuvant chemotherapy and recurrence must be ˃ 6 months.

  • Clinically significant toxicities from any prior systemic therapy or radiotherapy must have resolved to grade 0 or 1 as per National Cancer Institute (NCI) CTCAE v 5.0 - except alopecia, dry mouth, dysgeusia, dysphagia, and fatigue. Patients with a history of grade 3-4 cisplatin related neuropathy must have recovered to grade 0-2 prior to registration. Patients with a history of hearing impairment, or ototoxicity from prior cisplatin, of any grade are allowed.

  • No prior palliative RT within 30 days prior to registration unless the irradiated site(s) are not the target lesions. The irradiated site(s) also must not be the only sites of measurable recurrent disease.

  • No major surgical procedures within 30 days prior to registration.

  • No history of unstable angina requiring hospitalization within the last 6 months.

  • No history of myocardial infarction within the last 6 months.

  • New York Heart Association Functional Classification II or better (New York Heart Association [NYHA] Functional Classification III/IV are not eligible). Patients with symptomatic coronary artery disease, congestive heart failure or a known history of having a left ventricular ejection fraction < 50% must be stably controlled with medication in the opinion of the treating physician, in consultation with a cardiologist if appropriate.

  • No prior history of myocarditis.

  • No active infection requiring IV antibiotics, IV antiviral, or IV antifungal treatments at the time of study registration.

  • No history of (non-infectious) pneumonitis that required steroids or current pneumonitis requiring steroids and/or immunosuppressive therapy, idiopathic pulmonary fibrosis, drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans), or idiopathic pneumonitis.

  • No history of multi-drug resistant mycobacterium tuberculosis (TB) or active TB, as defined by systemic treatment received =< 2 years prior to registration. Note: Patients who had a history of treated TB ˃ 2 years prior to registration are allowed.

  • No prior solid organ transplant or bone marrow transplant.

  • No conditions requiring systemic treatment with either immunosuppressive doses of corticosteroids (> 10 mg daily prednisone or equivalents) or other immunosuppressive medications within 14 days of registration. Inhaled or topical steroids and adrenal replacement doses < 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Steroid premedication for the prophylaxis of CT contrast-related allergies is allowed. The use of dexamethasone as an anti-emetic premedication prior to chemotherapy is also allowed.

  • No active autoimmune disease requiring systemic treatment (i.e., disease modifying agents, corticosteroids, or immunosuppressive drugs) within the past 2 years. These may include (but not limited to) patients with a history of immune-related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), rheumatoid arthritis, connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, autoimmune hepatitis, glomerulonephritis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome.

    • Note: Patients are permitted to enroll if they have vitiligo; type I diabetes mellitus; hypothyroidism, pituitary or adrenal insufficiency requiring only hormone replacement; alopecia; and/or psoriasis not requiring systemic treatment. Conditions not expected to recur in the absence of an external trigger are permitted to enroll.

  • No prior live vaccine within 30 days prior to registration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist [registered trademark]) are live attenuated vaccines and are not allowed. Coronavirus disease 2019 (COVID-19) vaccines that are approved by the local drug regulatory authority of the participating region are allowed.

  • No known history of grade 3-4 allergic reaction or hypersensitivity reaction to cisplatin, carboplatin, or gemcitabine.

  • No known history of grade 4 hypersensitivity (or infusion) reaction to any monoclonal antibody. Patients who had prior grade 3 hypersensitivity (or infusion) reaction but could tolerate resumption of the antibody treatment after appropriate pre-medication are eligible.

  • PRIOR TO STEP 2 REGISTRATION:

  • Collection of plasma EBV DNA at baseline is mandatory for all patients prior to Step 2 registration and induction treatment.

    • Note: Submission of the baseline sample will be batch shipped.

  • PRIOR TO STEP 3 REGISTRATION/RANDOMIZATION: PATIENTS WITHOUT PROGRESSIVE DISEASE (PD) ONLY:

  • All patients must have received minimum of 3 cycles, and up to a maximum of 6 cycles of induction treatment within 20 weeks from cycle 1, day 1 of induction treatment (i.e., patients must have completed all induction treatment within 20 weeks from cycle 1 day 1, including the treatment breaks). Patients must have completed 6 cycles of induction treatment, except in the following circumstances:

    • Significant dose delays as a result of treatment-related toxicities.
    • Intercurrent illness(s), that rendered the patient unable to continue induction treatment.
    • Note: If a patient received < 6 cycles of induction treatment for reasons other than the above circumstances, they will not be eligible for randomization.

  • A CT scan within 30 days prior to Step 3 registration/randomization is required. If the most recent scan performed is not within this time frame, a repeat scan is required to assess response.

  • Did not meet any criteria that result in permanent discontinuation of study treatment during induction treatment phase.

  • Must meet the criteria for starting/resuming a new cycle of maintenance treatment.

  • Did not experience any nivolumab-related autoimmune toxicities that would result in permanent discontinuation of nivolumab during the induction treatment phase.

  • Collection of the plasma EBV DNA post-induction treatment is mandatory.

    • Note: Submission of the post-induction sample will be batch shipped.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Sequenzielle Zuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: Arm I (Nivolumab)

Patients receive nivolumab IV over 30 minutes. Cycles repeat every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI on study. Patients also undergo PET/CT or bone scan as clinically indicated.
Verfahren: Magnetic Resonance Imaging

Undergo MRI

Andere Namen:
  • MRT
  • Magnetresonanz
  • Magnetresonanztomographie-Scan
  • Medizinische Bildgebung, Magnetresonanz / Kernspinresonanz
  • HERR
  • MR-Bildgebung
  • MRT-Untersuchung
  • NMR-Bildgebung
  • NMRI
  • Kernspinresonanztomographie
  • Magnetresonanztomographie (MRT)
  • sMRT
  • Magnetresonanztomographie (Verfahren)
  • MRTs
  • Strukturelle MRT
Biologisch: Nivolumab

Given IV

Andere Namen:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumab-Biosimilar CMAB819
  • MDX1106
  • BMS 936558
  • ABP 206
  • Nivolumab Biosimilar ABP 206
  • BCD-263
  • Nivolumab-Biosimilar BCD-263
  • BMS936558
  • ONO 4538
  • ONO4538
Verfahren: Computed Tomography

Undergo CT or PET/CT

Andere Namen:
  • CT
  • KATZE
  • Computertomographie
  • Computergestützte axiale Tomographie
  • CT-Scan
  • Tomographie
  • Computerisierte Axialtomographie (Verfahren)
  • Computertomographie (CT)-Scan
  • Diagnosekatze Scan
  • Diagnose -Katzen -Scan -Service -Typ
Verfahren: Positron Emission Tomography

Undergo PET/CT

Andere Namen:
  • Medizinische Bildgebung, Positronen-Emissions-Tomographie
  • HAUSTIER
  • PET-Scan
  • Positronen-Emissions-Tomographie-Scan
  • Positronen-Emissions-Tomographie
  • Pt
  • Positronen-Emissions-Tomographie (Verfahren)
Verfahren: Bone Scan

Undergo bone scan

Andere Namen:
  • Knochenszintigraphie
Experimental: Arm II (Nivolumab, relatlimab)

Patients receive nivolumab IV over 30 minutes and relatlimab IV over 30-90 minutes. Cycles repeat every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI on study. Patients also undergo PET/CT or bone scan as clinically indicated.
Verfahren: Magnetic Resonance Imaging

Undergo MRI

Andere Namen:
  • MRT
  • Magnetresonanz
  • Magnetresonanztomographie-Scan
  • Medizinische Bildgebung, Magnetresonanz / Kernspinresonanz
  • HERR
  • MR-Bildgebung
  • MRT-Untersuchung
  • NMR-Bildgebung
  • NMRI
  • Kernspinresonanztomographie
  • Magnetresonanztomographie (MRT)
  • sMRT
  • Magnetresonanztomographie (Verfahren)
  • MRTs
  • Strukturelle MRT
Biologisch: Nivolumab

Given IV

Andere Namen:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumab-Biosimilar CMAB819
  • MDX1106
  • BMS 936558
  • ABP 206
  • Nivolumab Biosimilar ABP 206
  • BCD-263
  • Nivolumab-Biosimilar BCD-263
  • BMS936558
  • ONO 4538
  • ONO4538
Verfahren: Computed Tomography

Undergo CT or PET/CT

Andere Namen:
  • CT
  • KATZE
  • Computertomographie
  • Computergestützte axiale Tomographie
  • CT-Scan
  • Tomographie
  • Computerisierte Axialtomographie (Verfahren)
  • Computertomographie (CT)-Scan
  • Diagnosekatze Scan
  • Diagnose -Katzen -Scan -Service -Typ
Verfahren: Positron Emission Tomography

Undergo PET/CT

Andere Namen:
  • Medizinische Bildgebung, Positronen-Emissions-Tomographie
  • HAUSTIER
  • PET-Scan
  • Positronen-Emissions-Tomographie-Scan
  • Positronen-Emissions-Tomographie
  • Pt
  • Positronen-Emissions-Tomographie (Verfahren)
Biologisch: Relatlimab

Given IV

Andere Namen:
  • BMS-986016
  • BMS986016
  • Immunglobulin G4, Anti-(humanes Lymphozytenaktivierungsgen-3-Protein) (humane schwere Kette), Disulfid mit humaner leichter Kette, Dimer
  • BMS 986016
Verfahren: Bone Scan

Undergo bone scan

Andere Namen:
  • Knochenszintigraphie
Experimental: Induction therapy (Platinum-gemcitabine-nivolumab)

Patients receive nivolumab IV over 30 minutes on day 1 of each cycle, cisplatin IV or carboplatin IV over 30-60 minutes on day 1 of each cycle and gemcitabine IV over 30 minutes on days 1 and 8 of each cycle. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI and blood sample collection during screening and on study.
Arzneimittel: Carboplatin

Given IV

Andere Namen:
  • Blastocarb
  • Carboplat
  • Carboplatin Hexal
  • Carboplatino
  • Carboplatin
  • Carbosin
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatin
  • Paraplatin
  • Paraplatin AQ
  • Paraplatine
  • Platinwas
  • Ribocarbo
  • JM8
Arzneimittel: Cisplatin

Given IV

Andere Namen:
  • CDDP
  • Cis-Diamindichloridplatin
  • Cismaplat
  • Cisplatin
  • Neoplatin
  • Platinol
  • Abiplatin
  • Blastolem
  • Briplatin
  • Cis-Diammin-Dichlorplatin
  • Cis-Diamindichlorplatin (II)
  • Cis-Diamindichlorplatin
  • Cis-Dichloramin Platin (II)
  • Cis-Platindiamindichlorid
  • Cis-Platin
  • Cis-Platin II
  • Cis-Platin-II-Diamindichlorid
  • Cisplatyl
  • Citoplatino
  • Citosin
  • Cysplatyna
  • DDP
  • Lederplatin
  • Metaplatin
  • Peyrones Chlorid
  • Peyrones Salz
  • Platz
  • Kunststoff
  • Platamin
  • Platiblastin
  • Platiblastin-S
  • Platinex
  • Platinol- AQ
  • Platinol-AQ
  • Platinol-AQ VHA Plus
  • Platinoxan
  • Platin
  • Platindiaminodichlorid
  • Platiran
  • Plastin
  • Platosin
Verfahren: Biospecimen Collection

Undergo blood sample collection

Andere Namen:
  • Biologische Probensammlung
  • Bioprobe gesammelt
  • Probenentnahme
  • Beispielsammlung
Verfahren: Magnetic Resonance Imaging

Undergo MRI

Andere Namen:
  • MRT
  • Magnetresonanz
  • Magnetresonanztomographie-Scan
  • Medizinische Bildgebung, Magnetresonanz / Kernspinresonanz
  • HERR
  • MR-Bildgebung
  • MRT-Untersuchung
  • NMR-Bildgebung
  • NMRI
  • Kernspinresonanztomographie
  • Magnetresonanztomographie (MRT)
  • sMRT
  • Magnetresonanztomographie (Verfahren)
  • MRTs
  • Strukturelle MRT
Biologisch: Nivolumab

Given IV

Andere Namen:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumab-Biosimilar CMAB819
  • MDX1106
  • BMS 936558
  • ABP 206
  • Nivolumab Biosimilar ABP 206
  • BCD-263
  • Nivolumab-Biosimilar BCD-263
  • BMS936558
  • ONO 4538
  • ONO4538
Verfahren: Computed Tomography

Undergo CT or PET/CT

Andere Namen:
  • CT
  • KATZE
  • Computertomographie
  • Computergestützte axiale Tomographie
  • CT-Scan
  • Tomographie
  • Computerisierte Axialtomographie (Verfahren)
  • Computertomographie (CT)-Scan
  • Diagnosekatze Scan
  • Diagnose -Katzen -Scan -Service -Typ
Arzneimittel: Gemcitabine

Given IV

Andere Namen:
  • dFdCyd
  • dFdC
  • Difluordesoxycytidin

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Progression-free survival (PFS)
Zeitfenster: Time from randomization to progressive disease (PD) or death due to any cause, assessed up to 6 years

Will be assessed in both treatment arms and will be estimated using the Kaplan-Meier method. The comparison of PFS distributions between treatment arms will be performed using the log-rank test. Additional analyses of treatment effect will be performed using Cox models with the stratification factors included as a fixed covariates, as well as other tumor and patient characteristics, listed below. Median PFS and the corresponding 95% confidence intervals (CIs) for each arm will be estimated with the Brookmeyer-Crowley method. Multivariable analysis will be performed using a Cox proportional hazards model and relevant patient and tumor characteristics (country [Asian sites versus (vs.) Non-Asian sites], keratinizing squamous carcinoma, sex, age, and baseline Epstein-Barr virus (EBV) deoxyribonucleic acid [DNA]). Hazard ratios and their respective 85% lower confidence bound, and 95% confidence intervals will be provided.
Time from randomization to progressive disease (PD) or death due to any cause, assessed up to 6 years

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Overall survival (OS)
Zeitfenster: Time from randomization to death due to any cause, assessed up to 6 years

Will be estimated using the Kaplan-Meier method and between-arm differences will be assessed using the log-rank test. Median OS and the corresponding 95% CIs using log-log transformation to survival function for each arm will be estimated with the Brookmeyer-Crowley method.
Time from randomization to death due to any cause, assessed up to 6 years
Tumor response
Zeitfenster: Up to 6 years

Will be assessed using Response Evaluation Criteria in Solid Tumors version 1.1. Cox proportional hazards models will be used to determine hazard ratios (cause-specific hazard ratios in the case of endpoints with competing risks) and to assess the effects of covariates of interest. Fine-Gray sub-distribution hazards Cox model will be used to complement the competing risk analyses.
Up to 6 years
Locoregional failure
Zeitfenster: Up to 6 years

Cox proportional hazards models will be used to determine hazard ratios (cause-specific hazard ratios in the case of endpoints with competing risks) and to assess the effects of covariates of interest. Fine-Gray sub-distribution hazards Cox model will be used to complement the competing risk analyses.
Up to 6 years
Distant metastasis
Zeitfenster: Up to 6 years

Cox proportional hazards models will be used to determine hazard ratios (cause-specific hazard ratios in the case of endpoints with competing risks) and to assess the effects of covariates of interest. Fine-Gray sub-distribution hazards Cox model will be used to complement the competing risk analyses.
Up to 6 years
Incidence of adverse events (AEs)
Zeitfenster: Up to 6 years

Will be graded using Common Terminology Criteria for Adverse Events version 5.0. Counts of all AEs by grade will be provided by treatment arm. Counts and frequencies will be provided for the worst grade AE experienced by the patient by treatment arm. The rate of patients with at least 1 grade 3 or higher AE will be compared between the treatment arms using a chi-square test for proportions and confidence intervals for rate difference will be computed using Miettinen-Nurminen (score) method
Up to 6 years
Post-induction plasma EBV DNA as a prognostic biomarker
Zeitfenster: Up to 6 years

Will be defined as a binary biomarker (detectable: >= 1 copies/mL vs. undetectable: 0 copies/mL). Biomarker effect HRs from multivariable Cox models, including key tumor and patient characteristics will also be reported.
Up to 6 years
Pre-induction plasma EBV DNA vs. progressive disease (PD) during induction treatment
Zeitfenster: Up to 6 years

Will include all patients treated with concurrent (induction) treatment and a binary biomarker based on pre-induction plasma EBV DNA (< 2000 vs. ≥2000 copies/mL). PD rates during induction for each biomarker subgroup will be computed assuming a binomial distribution and compared between biomarker subgroups using a chi-square test. Multivariable Cox models, including key tumor and patient characteristics will also be included.
Up to 6 years
Persistent plasma EBV DNA vs. PFS
Zeitfenster: Up to 6 years

Will examine the association between persistent EBV DNA after induction treatment and PFS. Only randomized patients with positive pre-induction plasma EBV DNA will be included (~90-95%). Patients will be classified into "EBV DNA positive to negative" and "EBV DNA consistently positive" based on the pre-induction and post-induction EBV DNA. Multivariable Cox models, including key tumor and patient characteristics will also be included.
Up to 6 years

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Post-induction EBV DNA as a predictive biomarker
Zeitfenster: Up to 6 years

Will be assessed of the predictive role of post-induction EBV DNA on PFS and OS will be performed using the binary biomarker. Cox proportional hazards model with treatment arm, binary biomarker, and its interaction will be used for these analyses. Treatment effect hazard ratios and 95% confidence intervals will be reported. Adjusted HR estimates will be obtained after adding key patient and tumor characteristics.
Up to 6 years

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

National Cancer Institute (NCI)

Ermittler

  • Hauptermittler: Brigette B Ma, NRG Oncology

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

15. Juli 2024

Primärer Abschluss (Geschätzt)

30. April 2029

Studienabschluss (Geschätzt)

30. April 2029

Studienanmeldedaten

Zuerst eingereicht

7. September 2023

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

7. September 2023

Zuerst gepostet (Tatsächlich)

8. September 2023

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

6. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

5. November 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • NCI-2023-06678
  • U10CA180868 (US NIH Stipendium/Vertrag)
  • NCI-2023-06678 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
  • NRG-HN011 (Andere Kennung: CTEP)
  • NRG-HN011 (Andere Kennung: NRG Oncology)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren